Skip to main content
. 2016 Jul 15;6:29869. doi: 10.1038/srep29869

Table 5. The relationships between gene CNVs and prognosis of CRC.

CNV Genotypes Total patients (n = 323) P Valueb Colon cancer (n = 108) P Valuec Rectal cancer (n = 214) P Valuec
Patients (%) 5-Year Survival (%) 3-Year Survival (%) OS (Mean (SD)) (month) HR (95% CI)a Patients (%) 5-year survival (%) 3-year survival (%) OS (Mean (SD)) (month) HR (95% CI)a Patients (%) 5-year survival (%) 3-year survival (%) OS (Mean (SD)) (month) HR (95% CI)a
FBXW7
 Wt 255 (83.6) 59 68 74.00 (2.53) 1.00   88 (85.4) 62 71 77.32 (4.35) 1.00   166 (82.5) 58 68 72.48 (3.09) 1  
 Del 27 (8.9) 68 76 82.75 (7.61) 0.62 (0.29, 1.33) 0.220 10 (9.7) 48 70 68.95 (11.96) 1.09 (0.41, 2.88) 0.868 17 (8.5) 81 81 90.74 (9.01) 0.31 (0.07, 1.26) 0.100
 Amp 23 (7.5) 61 70 79.35 (8.18) 0.91 (0.46, 1.83) 0.793 5 (4.9) 20 40 35.40 (12.23) 3.39 (1.03, 11.18) 0.045 18 (9.0) 72 78 89.61 (7.71) 0.48 (0.18, 1.29) 0.146
Amp v.s. del + wt         0.95 (0.48, 1.90) 0.888         3.38 (1.05, 11.12) 0.045         0.51 (0.19, 1.38) 0.185
Del + amp v.s. wt         0.75 (0.44, 1.29) 0.299         1.57 (0.74, 3.34) 0.242         0.41 (0.18, 0.92) 0.031
MDM2
 Wt 298 (94.6) 60 68 74.28 (2.35) 1.00   99 (96.1) 56 68 73.5 (4.18) 1.00   198 (93.8) 60 69 74.97 (2.84) 1  
 Del 9 (2.9) 67 67 75.22 (14.09) 0.72 (0.23, 2.29) 0.580 4 (3.9) 75 75 81.25 (20.59) 0.62 (0.08, 4.61) 0.640 5 (2.4) 60 60 55.40 (13.56) 1.13 (0.27, 4.80) 0.867
 Amp 8 (2.5) 61 61 60.60 (9.15) 0.80 (0.25, 2.57) 0.707 0           8 (3.8) 61 61 60.60 (9.15) 0.96 (0.30, 3.13) 0.956
Amp v.s. del + wt         0.81 (0.25, 2.61) 0.727                     0.96 (0.30, 3.11) 0.949
Del + amp v.s. wt         0.76 (0.33, 1.75) 0.517         0.62 (0.08, 4.61) 0.640         1.03 (0.40, 2.61) 0.957
SKP2
 Wt 284 (95.3) 60 70 75.34 (2.39) 1.00   95 (95.0) 58 69 74.9 (44.23) 1.00   188 (95.5) 61 70 75.79 (2.90) 1  
 Del 6 (2.0) 50 67 68.50 (15.37) 1.31 (0.41, 4.17) 0.658 3 (3.0) 33 67 43.33 (16.85) 3.62 (0.80, 16.31) 0.094 3 (1.5) 67 67 84.00 (15.51) 0.75 (0.10, 5.55) 0.777
 Amp 8 (2.7) 42 42 50.03 (11.55) 1.39 (0.51, 3.79) 0.526 2 (2.0)     19.50 (3.89) 4.68 (0.57, 38.39) 0.151 6 (3.0) 46 46 53.83 (12.53) 0.99 (0.30, 3.22) 0.985
Amp v.s. del + wt         1.38 (0.50, 3.78) 0.531         4.47 (0.55, 36.48) 0.162         0.99 (0.31, 3.22) 0.990
Del + amp v.s. wt         1.35 (0.62, 2.91) 0.447         3.92 (1.13, 3.66) 0.032         0.93 (0.33, 2.54) 0.865
β-TRCP
 Wt 282 (91.0) 58 68 74.09 (2.42) 1.00   90 (89.1) 58 68 73.97 (4.41) 1.00   191 (91.8) 59 68 74.47 (2.89) 1  
 Del 4 (1.3) 100 100 90.53 (11.69)   0.962 3 (3.0) 100 100 86.00 (14.69)   0.976 1 (0.5) 100 100 79   0.971
 Amp 24 (7.7) 66 74 63.25 (5.44) 0.42 (0.19, 0.97) 0.050 8 (7.9) 50 75 61.00 (8.08) 0.61 (0.18, 2.03) 0.421 16 (7.7) 74 74 64.01 (7.04) 0.22 (0.06, 0.86) 0.029
Amp v.s. del + wt         0.44 (0.19, 1.01) 0.052         0.63 (0.19, 2.08) 0.444         0.22 (0.06, 0.86) 0.029
Del + amp v.s. wt         0.39 (0.17, 0.88) 0.023         0.50 (0.16, 1.57) 0.230         0.21 (0.06, 0.83) 0.026
NEDD4-1                                    
 Wt 269 (89.7) 59 68 74.39 (2.46) 1.00   89 (87.9) 56 68 73.35 (4.44) 1.00   181 (90.5) 60 68.4 75.23 (2.94) 1  
 Del 2 (0.6) 50 50 46.00 (23.34) 1.02 (0.14, 7.66) 0.985 0           2 (1.0) 50 50 46.00 (23.34) 0.85 (0.11, 6.81) 0.878
 Amp 29 (9.7) 65 72 74.79 (7.61) 0.82 (0.40, 1.70) 0.597 12 (12.1) 58 67 70.83 (12.27) 1.06 (0.41, 2.76) 0.900 17 (8.5) 77 76 70.12 (8.26) 0.73 (0.23, 2.35) 0.595
Amp v.s. del + wt         0.82 (0.40, 1.70) 0.597         1.06 (0.41, 2.76) 0.900         0.73 (0.23, 2.35) 0.595
Del + amp v.s. wt         0.84 (0.42, 1.67) 0.620         1.06 (0.41, 2.76) 0.900         0.75 (0.27, 2.09) 0.578

CI, confidence interval; HR, hazard ratio; OS, overall survival.

aadjusted for CEA and CA19-9 level before surgery, Dukes stage, pathological type and metastasis. bP < 0.05 in the survival analysis was considered statistically significant. cP < 0.025 in the stratified survival analysis by location was considered statistically significant.